The trial of a new drug to treat a form of breast cancer has been hailed as “groundbreaking”, with results said to show a strong trend towards improved overall survival.
Pharmaceutical company AstraZeneca said Enhertu demonstrated a 72% reduction in the risk of disease progression or death in women with HER2-positive metastatic breast cancer compared to a different medicine.
The results were presented in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2021.
The trial involving around 500 patients at multiple sites in Asia, Europe, North America, Oceania and South America found there was “a strong trend towards improved overall survival” with Enhertu.
But it was pointed out that this analysis is “not yet mature and is not statistically significant”.
AstraZeneca said that despite initial treatment with trastuzumab and a taxane, people with HER2-positive metastatic breast cancer will often experience disease progression.
The company said nearly all patients treated with Enhertu were alive at one year (94.1%) compared to 85.9% of patients treated with trastuzumab emtansine (T-DM1).
Susan Galbraith, executive vice president, Oncology R&D, said: “Today’s results are ground-breaking.”
She said Enhertu tripled progression-free survival as assessed by investigators, and provided a disease control rate exceeding 95% compared to 77% for trastuzumab emtansine.
“These unprecedented data represent a potential paradigm shift in the treatment of HER2-positive metastatic breast cancer, and illustrate the potential for Enhertu to transform more patient lives in earlier treatment settings,” she added.
Javier Cortes, from the International Breast Cancer Centre in Barcelona, said patients with previously treated HER2-positive metastatic breast cancer will typically experience disease progression in less than a year with available HER2-directed treatments.
He said the the “high and consistent benefit” seen across efficacy endpoints and key subgroups of patients receiving Enhertu is “remarkable and supports the potential of Enhertu to become the new standard of care for those who have previously been treated for HER2-positive metastatic breast cancer”.
Ken Takeshita, global head of R&D at Daiichi Sankyo, said: “These landmark data will form the basis of our discussions with global health authorities to potentially bring Enhertu to patients with previously treated HER2-positive metastatic breast cancer as a more effective treatment option as soon as possible.”
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here